LKB1 modulates lung cancer differentiation and metastasis
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Germline mutation in serine/threonine kinase 11 (STK11, also called LKB1) results in Peutz-Jeghers syndrome, characterized by intestinal hamartomas and increased incidence of epithelial cancers. Although uncommon in most sporadic cancers, inactivating somatic mutations of LKB1 have been reported in primary human lung adenocarcinomas and derivative cell lines. Here we used a somatically activatable mutant Kras-driven model of mouse lung cancer to compare the role of Lkb1 to other tumour suppressors in lung cancer. Although Kras mutation cooperated with loss of p53 or Ink4a/Arf (also known as Cdkn2a) in this system, the strongest cooperation was seen with homozygous inactivation of Lkb1. Lkb1-deficient tumours demonstrated shorter latency, an expanded histological spectrum (adeno-, squamous and large-cell carcinoma) and more frequent metastasis compared to tumours lacking p53 or Ink4a/Arf. Pulmonary tumorigenesis was also accelerated by hemizygous inactivation of Lkb1. Consistent with these findings, inactivation of LKB1 was found in 34% and 19% of 144 analysed human lung adenocarcinomas and squamous cell carcinomas, respectively. Expression profiling in human lung cancer cell lines and mouse lung tumours identified a variety of metastasis-promoting genes, such as NEDD9, VEGFC and CD24, as targets of LKB1 repression in lung cancer. These studies establish LKB1 as a critical barrier to pulmonary tumorigenesis, controlling initiation, differentiation and metastasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Beyond its role regulating metabolism via AMPK, LKB1 loss promotes tumorigenesis by reprogramming epigenetic states, facilitating lineage plasticity and promoting metastasis22,67–70.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [22]
In the citing paper
“Somatic deletion of Lkb1 is insufficient for initiation of lung carcinogenesis in mice as a singular event but dramatically accelerates KrasG12D-driven carcinogenesis and fosters early metastatic dissemination84.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [84]
In the citing paper
“In addition, loss of Lkb1 results in epigenetic reprogramming and an expanded tumor histological repertoire, with high incidence of squamous or adenosquamous carcinomas, in agreement with data supporting enrichment of LKB1 mutations in human adenosquamous NSCLC84–86.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [84]
In the citing paper
“Loss of p53 or expression of either dominant negative or dominant gain-of-function Trp53 mutants also co-operate with oncogenic Kras to induce LUADs with shortened latency and increased metastatic proclivity, although these tumors are less aggressive than those with Lkb1 loss69–71, 84.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [84]
Citations
Cites
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Bolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,266
Summaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,887 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Identification of Pancreatic Cancer Stem Cells
Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., Wicha, M., Clarke, M. F., & Simeone, D. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2030 · Cited by 3,339
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Self-citationRole of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
Molecular Definition of Breast Tumor Heterogeneity
Shipitsin, M., Campbell, L. L., Argani, P., Weremowicz, S., Bloushtain-Qimron, N., Yao, J., Nikolskaya, T., Serebryiskaya, T., Beroukhim, R., Hu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.01.013 · Cited by 1,353
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., & Jacks, T. (2001) · Nature · doi:10.1038/35074129 · Cited by 1,179 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Self-citationThe LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,077
Self-citation
Cited by
Items 601–700 of 1,000
Novel insights into the molecular origins and treatment of lung cancer
Webb, J. D., & Simon, M. C. (2010) · Cell Cycle · doi:10.4161/cc.9.20.13588 · Cited by 24
An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo
Tomoshige, K., Guo, M., Tsuchiya, T., Fukazawa, T., Fink-Baldauf, I. M., Stuart, W. D., Naomoto, Y., Nagayasu, T., & Maeda, Y. (2018) · Oncogene · doi:10.1038/s41388-018-0240-1 · Cited by 21
Opportunities and Challenges of Kava in Lung Cancer Prevention
Freeman, B., Mamallapalli, J., Bian, T., Ballas, K., Lynch, A. M., Scala, A., Huo, Z., Fredenburg, K. M., Bruijnzeel, A. W., Baglole, C. J., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119539 · Cited by 23
“Specifically, mice with LKB1 loss of function in conjunction with K-ras [75], PTEN [76] or SOX2 [77] developed metastatic lung tumors of varied pathologies, including ADC, SCC, and large-cell carcinoma.”
BackgroundUnderstanding cachexia and its impact on lung cancer and beyond
Yue, M., Qin, Z., Hu, L., & Ji, H. (2024) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2024.02.003 · Cited by 25
“188 , 189 One study identified tumor live kinase B1 loss as a driver of cancer cachexia that serves as a genetic biomarker for this wasting syndrome in patients with lung cancer.”
Self-citationCai, Z., Satyanarayana, G., Song, P., Zhao, F., You, S., Liu, Z., Mu, J., Ding, Y., He, B., & Zou, M. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae187 · Cited by 21
Barouki, R., & Coumoul, X. (2010) · Cell Adhesion & Migration · doi:10.4161/cam.4.1.10313 · Cited by 22
Dcas Supports Cell Polarization and Cell-Cell Adhesion Complexes in Development
Tikhmyanova, N., Tulin, A. V., Roegiers, F., & Golemis, E. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012369 · Cited by 23
“Overexpression of NEDD9 supports oncogenic signaling in malignancies of the hematopoietic system [13,29–32], and has been linked to increased cellular invasive behavior in breast and colorectal cancer cell lines [18,33], squamous cell carcinomas of the head and neck [34], and enhanced metastatic potential in glioblast…”
BackgroundEggers, C. M., Kline, E. R., Zhong, D., Zhou, W., & Marcus, A. I. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.316422 · Cited by 20
“This is in contrast to LKB1, which when depleted or knocked-out in a mouse model induces metastasis (39, 40), thereby serving as a metastasis suppressor.”
ResultSTK11 is required for the normal program of ciliated cell differentiation in airways
Chu, Q., Yao, C., Qi, X., Stripp, B. R., & Tang, N. (2019) · Cell Discovery · doi:10.1038/s41421-019-0104-z · Cited by 20
Zyla, R. E., Hahn, E., & Hodgson, A. (2021) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2021-207906 · Cited by 26
Roles of Hippo signaling in lung cancer
Zhang, H.-X., Wang, Y., Ding, W., Chen, C., Niu, Z., & Pan, M. (2015) · Indian Journal of Cancer · doi:10.4103/0019-509x.168949 · Cited by 21
Ratovitski, E. A. (2010) · Oxidative Medicine and Cellular Longevity · doi:10.4161/oxim.3.5.13108 · Cited by 22
“LKB1 tumor suppressor gene (also known as serine/threonine kinase-11, STK11) is capable to regulate other protein’s function by phosphorylation, thereby affecting cell proliferation and survival.(15-21) Smoking has been linked to human epithelial cancers, which overexpress proteins implicated in inflammatory signaling…”
BackgroundBleau, A., Freire, J., Pajares, M. J., Zudaire, I., Antón, I., Nistal‐Villán, E., Redrado, M., Zandueta, C., Garmendia, I., Ajona, D., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28574 · Cited by 20
“Indeed, concomitant KRAS mutation with inactivation of tumor suppressors (such as p53, Lkb1 and Ink4a/Arf) are required in GEMMs for the development of aggressive lung tumors.(40) The deletion of WWOX in Lacun cells might represent the double alteration necessary to induce carcinogenesis and increase aggressiveness in…”
BackgroundHu, G., Huang, N., Zhang, J., Zhang, D., Wang, S., Zhang, Y., Wang, L., Du, Y., Kuang, S., Ma, K., et al. (2023) · Molecular Carcinogenesis · doi:10.1002/mc.23606 · Cited by 23
“cancer progression by mediating cytosolic translocation of CRTC1 from the nucleus to regulate NEDD9 transcription.(17,18) However, more studies are needed to determinate the detailed mechanisms of LKB1 in CRC.”
BackgroundExperimental models for cancer brain metastasis
Liu, Z., Dong, S., Liu, M., Liu, Y., Ye, Z., Zeng, J., & Yao, M. (2023) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2023.10.005 · Cited by 22
“77 Despite tremendous efforts, a robust mouse model of lung cancer with brain metastasis remains lacking.”
BackgroundFN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion
Whitsett, T. G., Ensign, S. P. F., Dhruv, H., Inge, L. J., Kurywchak, P. A., Wolf, K. K., Lobello, J. R., Kingsley, C. B., Allen, J. W., Weiss, G. J., et al. (2014) · Clinical & Experimental Metastasis · doi:10.1007/s10585-014-9653-6 · Cited by 19
“Transient expression of Cre and subsequent expression of KRAS and homozygous deletion of LKB1 within the lungs of the KRAS/LKB1 mice results in multi-focal, highly aggressive NSCLC with both local and distant metastases [25, 26].”
BackgroundResultLee, S. M., Choi, J. E., Na, Y. K., Lee, E. J., Lee, W. K., Choi, Y. Y., Yoon, G. S., Jeon, H., Kim, D. S., & Park, J. Y. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.04.013 · Cited by 19
Stereotactic Body Radiation Therapy Delivery in a Genetically Engineered Mouse Model of Lung Cancer
Du, S., Lockamy, V. L., Zhou, L., Xue, C., LeBlanc, J. M., Glenn, S., Shukla, G., Yu, Y., Dicker, A. P., Leeper, D. B., et al. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.07.008 · Cited by 21
“The mouse strain harboring a conditional activating mutation (G12D) at the endogenous Kras locus has been described previously (12).”
BackgroundLi, L., Yu, C., Ren, J., Ye, S., Ou, W., Wang, Y., Yang, W., Zhong, G., Chen, X., Shi, H., et al. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1607-5 · Cited by 19
Self-citationFrom mice to men: GEMMs as trial patients for new NSCLC therapies
Hayes, S. A., Hudson, A. L., Clarke, S. J., Molloy, M. P., & Howell, V. M. (2014) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2014.04.002 · Cited by 24
The LKB1 Tumor Suppressor as a Biomarker in Mouse and Human Tissues
Nakada, Y., Stewart, T. G., Peña, C. G., Zhang, S., Zhao, N., Bardeesy, N. M., Sharpless, N. E., Wong, K., Hayes, D. N., & Castrillón, D. H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073449 · Cited by 19
“Breeding of LSLKras; Lkb1 mice and Adeno-Cre nasal instillation to effect bronchial Cre-mediated recombination was conducted as previously described [2].”
MethodResultSelf-citationStem cells and lung cancer: future therapeutic targets?
Alison, M. R., Brenne, A. C. L., & Islam, S. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903103803 · Cited by 19
“In animal models the homozygous loss of Lkb1 in combination with K-ras mutation produces considerably more aggressive lung tumours than those produced by mutant K-ras alone [49].”
BackgroundExpression and transcriptional profiling of the LKB1 tumor suppressor in cervical cancer cells
Zhang, X., Chen, H., Wang, X., Zhao, W., & Chen, J. J. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.04.050 · Cited by 19
“Importantly, somatic LKB1mutations are frequently found in a significant number of sporadic non-small cell lung carcinomas (approximately 30%) [2].”
LKB1 Mutations Frequently Detected in Mucinous Bronchioloalveolar Carcinoma
Osoegawa, A., Kometani, T., Nosaki, K., Ondo, K., Hamatake, M., Hirai, F., Takumi, S. E. T. O., Sugio, K., & Ichinose, Y. (2011) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyr102 · Cited by 20
“MUTATIONS IN KRAS, EGFR AND P53 A KRAS mutation was observed in four tumors: G12D in two and G12C and G12V in one each.”
BackgroundInfluentialKoenig, M. J., Agana, B. A., Kaufman, J. M., Sharpnack, M. F., Wang, W. Z., Weigel, C., Navarro, F. C. P., Amann, J. M., Cacciato, N., Arasada, R. R., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3199 · Cited by 18
“Introduction LKB1 is a serine-threonine kinase responsible for regulation of cell polarity and the AMPK signaling pathway(1-5).”
Targeting Genomic Alterations in Squamous Cell Lung Cancer
Mantripragada, K. C., & Khurshid, H. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00195 · Cited by 20
NSP-CAS Protein Complexes: Emerging Signaling Modules in Cancer
Wallez, Y., Mace, P. D., Pasquale, E. B., & Riedl, S. J. (2012) · Genes & Cancer · doi:10.1177/1947601912460050 · Cited by 19
Donnelly, L. L., Hogan, T. C., Lenahan, S. M., Nandagopal, G., Eaton, J. G., Lebeau, M. A., McCann, C., Sarausky, H. M., Hampel, K. J., Armstrong, J. D., et al. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab104 · Cited by 18
“Given the clinical data demonstrating patients with KRAS-driven NSCLC lacking functional STK11 respond poorly to anti-PD-1 monotherapy (10), our analyses of un- and under-characterized STK11 variants provides critical pre-clinical evidence that can be used to help guide oncologic care for the ~15 000 patients diagnose…”
InfluentialPosttranslational regulation of liver kinase B1 in human cancer
Hu, L., Liu, M., Tang, B., Li, Q., Pan, B., Xu, C. S., & Lin, H. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104570 · Cited by 19
Oncoprotein SET-associated transcription factor ZBTB11 triggers lung cancer metastasis
Xu, W., Yao, H., Wu, Z., Yan, X., Jiao, Z., Liu, Y., Zhang, M., & Wang, D. (2024) · Nature Communications · doi:10.1038/s41467-024-45585-5 · Cited by 25
“…of oncogenic Kras and inactivation of Lkb1 have been well-established strategies to induce sporadic lung tumors with distal metastasis 64 – 66 , we then introduced a Kras +/LSL-G12D , Lkb1 Fl/Fl , Rosa26-e(CAG-LSL-Luc-EGPF) mouse model, in which lung tumor formation and metastasis can be…”
BackgroundPP2A phosphatase suppresses function of the mesenchymal invasion regulator NEDD9
Bradbury, P., Mahmassani, M., Zhong, J., Turner, K., Paul, A., Verrills, N. M., & O’Neill, G. M. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.10.011 · Cited by 18
Dependency of human and murine LKB1-inactivated lung cancer on aberrant CRTC-CREB activation
Zhou, X., Li, J. W., Chen, Z., Wei Min, N. I., Li, X., Yang, R., Shen, H., Liu, J., DeMayo, F. J., Lu, J., et al. (2021) · eLife · doi:10.7554/elife.66095 · Cited by 20
“Importantly, LKB1 loss has been shown to promote cancer progression and increase metastatic potential in the genetically engineered mouse models of lung cancer, melanoma, pancreatic cancer, and endometrial cancer ( Hermanova et al., 2020 ; Ji et al., 2007 ; Liu et al., 2012 ; Pen˜a et al., 2015 ).”
Toyokawa, G., Bersani, F., Bironzo, P., Picca, F., Tabbò, F., Haratake, N., Takenaka, T., Seto, T., Yoshizumi, T., Novello, S., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103966 · Cited by 23
Jung, S., Choi, Y. J., Kim, M. S., Baek, I.-P., Lee, S. H., Lee, A., Hur, S. Y., Kim, T., Lee, S. H., & Chung, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.2981 · Cited by 18
“S216F mutation was found in lung cancers [17], suggesting that the recurrent mutation may be a driver in cancer pathogenesis, including transition from CIN to CSCC.”
BackgroundGleeson, F. C., Kipp, B. R., Levy, M. J., Voss, J. S., Campion, M. B., Minot, D. M., Tu, Z. J., Klee, E. W., Lazaridis, K. N., & Kerr, S. E. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000391 · Cited by 18
“In murine models, STK11deficient tumors demonstrated more frequent metastasis when compared with tumors with TP53 alterations.(8) Concomitant STK11/KRAS mutant non–small-cell lung cancer cell lines are sensitive to dual threonine and tyrosine recognition kinase (MEK) inhibitors and may be suitable for mTOR-targeted th…”
BackgroundLkb1 Loss Promotes Tumor Progression of BRAFV600E-Induced Lung Adenomas
González‐Sánchez, E., Martín‐Caballero, J., Flores, J. M., Hernández‐Losa, J., Montero, M. Á., Cortés, J., Marés, R., Barbacid, M., & Recio, J. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066933 · Cited by 20
“latency, an expanded histological spectrum (adeno-, squamous and large-cell carcinoma) and more frequent metastasis compared to tumors mutated in Kras lacking p53 or p16/p19 [19].”
BackgroundMouse models in squamous cell lung cancer: impact for drug discovery
Singh, A. P., Herrera, D. A., Zhang, Y., Perez-Soler, R., & Cheng, H. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1437137 · Cited by 18
Nanog maintains stemness of Lkb1‐deficient lung adenocarcinoma and prevents gastric differentiation
Tong, X., Chen, Y., Zhu, X., Ye, Y., Xue, Y., Wang, R., Gao, Y., Zhang, W., Gao, W., Xiao, L., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202012627 · Cited by 21
“KL tumors are defined as a unique molecular subtype and are notorious for their strong tumor plasticity, allowing multiple cell lineage trans-differentiation programs including ADC, SCC, and mixed adeno-squamous cell carcinoma (Ad-SCC) (Ji et al, 2007).”
BackgroundSelf-citationTang, Z., Jiang, S., Du, R., Petri, E. T., El-Telbany, A., Chan, P. S. O., Kijima, T., Dietrich, S., Matsui, K., Kobayashi, M., et al. (2008) · Oncogene · doi:10.1038/onc.2008.411 · Cited by 18
“, 2005a) and tumor-suppressor role of LKB1 (Ji et al., 2007) in lung cancer.”
Persistent lineage plasticity driving lung cancer development and progression
Meng, F., Li, J., Xia, Z., Wang, Q., Sun, Q., Wang, S., Xu, L., & Yin, R. H. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70458 · Cited by 22
“95–98”
AMP-activated protein kinase — a journey from 1 to 100 downstream targets
Hardie, D. G. (2022) · Biochemical Journal · doi:10.1042/bcj20220255 · Cited by 19
Liang, X., Li, Z., Jiang, L., Guo, Q., Liu, M., & Nan, K. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2351 · Cited by 17
“Some studies demonstrated that LKB1 is a critical barrier to pulmonary tumorigenesis, controlling initiation, differentiation and metastasis (16).”
BackgroundPractical Use of Advanced Mouse Models for Lung Cancer
Safari, R., & Meuwissen, R. L. J. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2297-0_5 · Cited by 20
Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice
Bu, W., Creighton, C. J., Heavener, K. S., Gutiérrez, C., Dou, Y., Ku, A. T., Zhang, Y., Jiang, W., Urrutia, J. M., Jiang, W., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade0059 · Cited by 20
Identification and validation of PROM1 and CRTC2 mutations in lung cancer patients
He, Y., Li, Y., Qiu, Z., Zhou, B., Shi, S., Zhang, K., Luo, Y., Huang, Q., & Li, W. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-19 · Cited by 17
“found that LKB1 mutations are detected in human tumor samples, including lung cancer [35].”
BackgroundK‐RasV14I‐induced Noonan syndrome predisposes to tumour development in mice
Hernández‐Porras, I., Schuhmacher, A. J., Garcia‐Medina, R., Jiménez, B., Cañamero, M., de Martino, A., & Guerra, C. (2016) · The Journal of Pathology · doi:10.1002/path.4719 · Cited by 16
“Although K-Ras oncogenes and p16Ink4a/p19Arf loss cooperate, accelerating PDAC and lung tumour development in mouse models [34,45,46], no other tumours were found in K-RasV14I;p16Ink4a/p19Arf −/− mice.”
BackgroundBian, T., Wang, Y., Botello, J. F., Hu, Q., Jiang, Y., Zingone, A., Ding, H., Wu, Y., Aly, F. Z., Salloum, R. G., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02410-x · Cited by 16
Sahu, P., Donovan, C., Paudel, K. R., Pickles, S., Chimankar, V., Kim, R., Horvart, J. C., Dua, K., Ieni, A., Nucera, F., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1260411 · Cited by 16
Li, M., Kong, X., Jian, X., Bo, Y., Miao, X., Chen, H., Shang, P., Zhou, X., Wang, L., Zhang, Q., et al. (2024) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2024.173222 · Cited by 18
Autochthonous murine models for the study of smoker and never-smoker associated lung cancers
Akbay, E. A., & Kim, J. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.06.04 · Cited by 17
Kwon, M., Hong, J. Y., Kim, S. T., Kim, K., & Lee, J. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.152947 · Cited by 17
Berthelsen, M. F., Leknes, S. L., Riedel, M., Pedersen, M. A., Joseph, J. V., Hager, H., Vendelbo, M. H., & Thomsen, M. K. (2021) · Cancers · doi:10.3390/cancers13050974 · Cited by 16
“Interestingly, our data indicated a preference for activation mutation of Kras to co-occur with loss of Stk11 as has been observed in more classical mouse studies [9].”
BackgroundResultLi, L., Li, Z., Qu, J., Wei, X., Suo, F., Xu, J., Liu, X., Chen, C., & Zheng, S. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17057 · Cited by 18
The Marine-Derived Macrolactone Mandelalide A Is an Indirect Activator of AMPK
Mattos, D. R., Wan, X., Serrill, J., Nguyen, M. H., Humphreys, I., Viollet, B., Smith, A. B., McPhail, K. L., & Ishmael, J. E. (2022) · Marine Drugs · doi:10.3390/md20070418 · Cited by 16
“LKB1 is frequently deleted or mutated in human NSCLC cells and is considered a clinically significant mutation [28].”
BackgroundHülsmann, H., Rolff, J., Bender, C., Jarahian, M., Korf, U., Herwig, R., Fröhlich, H., Thomas, M., Merk, J., Fichtner, I., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.09.001 · Cited by 17
“Furthermore, LKB1, a known upstream activator of AMPK signaling, has been described as tumor suppressor in lung cancer cells and mouse tumors (Ji et al., 2007; Gill et al., 2011).”
BackgroundWeinberg, B. A., Gowen, K. A., Lee, T. K. M., Ou, S. I., Bristow, R., Krill, L. S., Almira-Suarez, M. I., Ali, S. M., Miller, V. A., Liu, S. V., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2015-0511 · Cited by 17
“Somatic alterations in STK11 are seen in about one third of lung adenocarcinomas, and STK11 encodes the LKB1 protein, which inhibits angiogenesis; loss-of-function mutations promote cell growth and metastasis [25, 26].”
BackgroundInvolvement of NADPH Oxidase 1 in Liver Kinase B1-Mediated Effects on Tumor Angiogenesis and Growth
Zulato, E., Ciccarese, F., Nardo, G., Pinazza, M., Agnusdei, V., Silic‐Benussi, M., Ciminale, V., & Indraccolo, S. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00195 · Cited by 17
“The liver kinase B1 (LKB1) is a serine threonine kinase, whose hereditable mutations are associated with the Peutz-Jeghers syndrome and is somatically mutated or deleted in certain tumor types, with relatively high frequencies in non-small cell lung cancer (NSCLC) and cervical carcinoma (5).”
BackgroundMillien, G., Cao, Y. X., O’Hara, C., Tagne, J., Hinds, A., Williams, M. C., Ramirez, M. I., & Kathuria, H. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9912-z · Cited by 16
Lv, S.-L., Zhou, X., Li, Y.-J., Luo, L., & Huang, D. (2023) · Journal of Cancer · doi:10.7150/jca.86572 · Cited by 15
“Notably, STK11/LKB1 has been found to be dysregulated in various types of tumors [27, 28], with lung adenocarcinoma exhibiting a higher incidence of mutations [29].”
BackgroundBi-steric mTORC1 inhibitors induce apoptotic cell death in tumor models with hyperactivated mTORC1
Du, H., Yang, Y. C., Liu, H.-J., Yuan, M., Asara, J. M., Wong, K., Henske, E. P., Singh, M., & Kwiatkowski, D. J. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167861 · Cited by 15
“Phone: 857.307.0781; Email: dk@rics.bwh.harvard.edu. mice at the age of 6 weeks (53).”
InfluentialSelf-citationIbarra-Arellano, M. A., Caprio, L., Hada, A., Stotzem, N., Cai, L. L., Shah, S. B., Walsh, Z. H., Melms, J. C., Wünnemann, F., Bestak, K., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-07796-4 · Cited by 15
Fang, X., Yin, Z., Li, X., Xia, L., Quan, X., Zhao, Y., & Zhou, B. (2017) · Oncotarget · doi:10.18632/oncotarget.14836 · Cited by 15
Zarredar, H., Farajnia, S., Ansarin, K., Baradaran, B., Aria, M., & Asadi, M. (2019) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520619666190301125203 · Cited by 16
Hamad, S. H., Montgomery, S. A., Simon, J. M., Bowman, B. M., Spainhower, K. B., Murphy, R. M., Knudsen, E. S., Fenton, S. E., Randell, S. H., Holt, J. R., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02348-0 · Cited by 18
“Based upon previous studies using lung cancer GEMMs, we expected to observe a higher number of tumors in the Trp53;p16 GEMM after activation of the mutant Nrf2 allele [32, 34, 59, 60].”
BackgroundMethodSelf-citationWang, T., Guo, H., Li, Q., Wu, W., Yu, M., Zhang, L., Li, C., Song, J., Wang, Z., Zhang, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111210 · Cited by 17
Girdin Promotes Tumorigenesis and Chemoresistance in Lung Adenocarcinoma by Interacting with PKM2
Cao, F., Yang, D., Tang, F., Lu, C., He, X., Chen, S., Yang, Z., Gong, S., Sun, L., Enomoto, A., et al. (2022) · Cancers · doi:10.3390/cancers14225688 · Cited by 15
Peroxiredoxin 1 is involved in disassembly of flagella and cilia
Gong, F., Liu, H., Li, J., Xue, L., & Zhang, M. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.01.081 · Cited by 15
Jian, S., Hsiao, C., Chen, S., Weng, C., Kuo, T., Wu, D., Hung, W., & Cheng, K. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0487 · Cited by 18
“lymph node metastases were observed in more than half of the activated KRAS x LKB1 knockout mice (5, 6).”
BackgroundHe, N., Kim, N., Song, M., Park, C., Kim, S., Park, E. Y., Yim, H. Y., Kim, K., Park, J. H., Kim, K. I., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0297 · Cited by 15
“Together with KRAS (20) and CDKN2A (21), STK11 (18) was consistently found to be one of three major mutations in non–small cell lung cancer (NSCLC) subtype of tissue and cell line samples (Fig.”
BackgroundMethodInfluentialAdvances in Immunocompetent Mouse and Rat Models
Bu, W., & Li, Y. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041328 · Cited by 17
Clinicopathologic characteristics and outcomes for patients with KRAS G12D-mutant NSCLC
Cooper, A. J., Muzikansky, A., Lennerz, J., Narinesingh, F., Mino-Kenudson, M., Hung, Y. P., Piotrowska, Z., Dagogo-Jack, I., Sequist, L. V., Gainor, J. F., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100390 · Cited by 14
Langeveld, D., Jansen, M., de Boer, D. V., van Sprundel, M., Brosens, L. A. A., Morsink, F. H. M., Giardiello, F. M., Offerhaus, G. J. A., & de Leng, W. W. J. (2011) · Gut · doi:10.1136/gutjnl-2011-300622 · Cited by 14
Xu, X. M., Zhu, H., Yang, M., Zheng, E., Zhou, Y., Ni, J., Li, R., Yang, Z., He, T., & Zhao, G. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.8358 · Cited by 14
Xie, C., Zhu, J., Yang, X., Huang, C., Zhou, L., Meng, Z., Li, X., & Zhong, C. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.645402 · Cited by 14
“The inactivation of specific tumor suppressor genes is also correlated with lung cancer progression (Ji et al., 2007; Lin et al., 2010; Li et al., 2019).”
BackgroundTanaka, I., & Morise, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010245 · Cited by 16
LKB1 deficiency upregulates RELM-α to drive airway goblet cell metaplasia
Yu, L., Zhang, Q., Li, L., Hao, D., Cheng, P., Li, K., Li, X., Wang, J., Wang, Q., Du, Z., et al. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-04044-w · Cited by 15
Self-citationLiver kinase B1 (LKB1) in the pathogenesis of UVB-induced murine basal cell carcinoma
Byekova, Y. A., Herrmann, J. L., Xu, J., Elmets, C. A., & Athar, M. (2011) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2011.01.006 · Cited by 14
“In addition, sporadic inactivating mutations of LKB1 have also been implicated in the pathogenesis of some lung and cervical carcinomas as well as a number of other epithelial cancers [8,9].”
BackgroundOverview of KRAS‐Driven Genetically Engineered Mouse Models of Non‐Small Cell Lung Cancer
Sheridan, C., & Downward, J. (2015) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph1435s70 · Cited by 14
LKB1 mutations and their correlation with LKB1 and Rheb expression in bladder cancer
Tigli, H., Seven, D., Tunç, M., Şanlı, Ö., Başaran, Ş., Ulutin, T., & Buyru, N. (2012) · Molecular Carcinogenesis · doi:10.1002/mc.21902 · Cited by 13
“cervical cancers [48], colon cancers [49], and lung cancers [50].”
BackgroundMomcilovic, M., Bailey, S. T., Lee, J. T., Zamilpa, C., Jones, A. E., Abdelhady, G., Mansfield, J. R., Francis, K. P., & Shackelford, D. B. (2018) · Journal of Visualized Experiments · doi:10.3791/57167 · Cited by 24
Mouse models of lung squamous cell carcinomas
You, M. S., Rouggly, L. C., You, M., & Wang, Y. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9406-4 · Cited by 13
Zhang, J., Nannapaneni, S., Wang, D., Liu, F., Wang, X., Jin, R., Liu, X., Rahman, M. A., Peng, X., Qian, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19779 · Cited by 14
“While the loss of LKB1 promotes lung cancer metastasis [22], LKB1 also functions as a master regulator of cell metabolism through activation of the downstream AMPK signaling pathway [23].”
BackgroundSelf-citationZhang, Y., Ma, Y., Li, Y., Shen, X., Yu, Y., Pan, Y., Zhang, Y., Zheng, D., Zhao, Y., Ye, T., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-02828-5 · Cited by 13
Thakur, C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815720-6.00002-2 · Cited by 17
Xu, L., Xu, F., Kong, Q., Yang, T., Tan, D., Zhang, X., Li, N., Zhao, S., Zhao, J., & Li, M. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23215 · Cited by 13
“pulmonary tumorigenesis, controlling initiation, differentiation, and metastasis.(33) De novo mouse models also showed that silencing of”
BackgroundLi, Z., Ding, B., Xu, J., Mao, K., Zhang, P., & Xue, Q. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.580027 · Cited by 13
FoxO3a gene is a target of deletion in mouse lung adenocarcinoma
Herzog (2009) · Oncology Reports · doi:10.3892/or_00000507 · Cited by 13
Stem Cell Biology in the Lung and Lung Cancers: Using Pulmonary Context and Classic Approaches
Raiser, D. M., Zacharek, S. J., Roach, R. R., Curtis, S. J., Sinkevicius, K. W., Gludish, D. W., & Kim, C. F. (2008) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2008.73.036 · Cited by 15
“…regulator of the PI3K/TOR (target of rapamycin) pathway, is frequently mutated in lung cancers, and its disruption is the most potent genetic event collaborating with oncogenic K-ras induction in lung tumorigenesis (Ji et al. 2007); whether mutation of LKB1 affects BASC activity is unknown.”
BackgroundGenetically Engineered Knock-In and Conditional Knock-In Mouse Models of Cancer
Rappaport, A., & Johnson, L. (2014) · Cold Spring Harbor Protocols · doi:10.1101/pdb.top069799 · Cited by 14
Metabolic Phenotypes, Dependencies, and Adaptation in Lung Cancer
DeNicola, G. M., & Shackelford, D. B. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037838 · Cited by 13
Kwon, J. J., Dilly, J., Liu, S., Kim, E., Bian, Y., Dharmaiah, S., Tran, T. H., Kapner, K. S., Ly, S. H., Yang, X., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.22.618529 · Cited by 15
Molecular hydrogen: Mechanism against oxidative stress and application in periodontitis: A review
Ying, J., Zhang, K., Huang, Y., Zhu, X., Ruan, Y., Lin, H., & Wu, G. (2025) · Medicine · doi:10.1097/md.0000000000041800 · Cited by 13
Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets
Drosten, M., & Barbacid, M. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1360-5 · Cited by 12
“Moreover, they induce metastasis more frequently than those GEMMs carrying mutations in the p53 tumor suppressor [38, 39].”
BackgroundMARK2 inhibits the growth of HeLa cells through AMPK and reverses epithelial-mesenchymal transition
Xu, G., Ge, Y., Tao, X., Gao, Q., & Liang, X. (2017) · Oncology Reports · doi:10.3892/or.2017.5686 · Cited by 12
Leukocyte CH25H is a potential diagnostic and prognostic marker for lung adenocarcinoma
Zhang, J., Xu, L., Gao, J., Li, J., Zhao, X., Yang, P., Ge, Y., Guo, D., Liu, Z., Wang, X., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-24183-9 · Cited by 12
Pathogenic mutation hotspots in protein kinase domain structure
Medvedev, K. E., Schaeffer, R. D., Pei, J., & Grishin, N. V. (2023) · Protein Science · doi:10.1002/pro.4750 · Cited by 12
“D274 locates in activation loop of kinase domain and includes mutations from two genes: BRAF (melanoma [Maldonado et al., 2003]) and STK11 (lung cancer [Ji et al., 2007]).”
BackgroundMYCN Amplifications and Metabolic Rewiring in Neuroblastoma
Pouliou, M., Koutsi, M. A., Champezou, L., Giannopoulou, A.-I., Vatsellas, G., Piperi, C., & Agelopoulos, M. (2023) · Cancers · doi:10.3390/cancers15194803 · Cited by 12
“A wealth of examples describes the rewiring of pathways between later and initial stages of cancer phenotypes [13–15].”
BackgroundPark, M. A., Whelan, C. J., Ahmed, S., Boeringer, T., Brown, J. S., Carson, T. L., Crowder, S. L., Gage, K. L., Gregg, C. J., Jeong, D. K., et al. (2024) · Cancers · doi:10.3390/cancers16132364 · Cited by 18
“…between nutrition coaching and body weight maintenance in n = 10 patients with CAC during treatment [155], while a study conducted in n = 58 undernourished cancer patients predominately lung, head and neck, colorectal, and breast cancer was not associated with improvements in body weight [156].”
ResultManagement of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine
Aredo, J. V., & Padda, S. K. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0557-6 · Cited by 12
Zhang, K., Wang, J., Wang, J., Luh, F., Liu, X., Yang, L., Liu, Y., Su, L., Yang, Y. S. H., Chu, P. G., et al. (2019) · American Journal of Cancer Research · Cited by 14
Metadata
- Authors
- Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., Liang, M.-C., Cai, D., Naumov, G. N., Bao, L., Contreras, C. M., Li, D., Chen, L., Krishnamurthy, J., Koivunen, J., Chirieac, L. R., Padera, R. F., Bronson, R. T., Lindeman, N. I., Christiani, D. C., Lin, X., Shapiro, G. I., Jänne, P. A., Johnson, B. E., Meyerson, M., Kwiatkowski, D. J., Castrillon, D. H., Bardeesy, N., Sharpless, N. E., & Wong, K.-K.
- Affiliations
- Dana-Farber Cancer Institute (US)
- University of North Carolina at Chapel Hill (US)
- Harvard University (US)
- University of Tennessee Health Science Center (US)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Brigham and Women's Hospital (US)
- Broad Institute (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Bardeesy, Nabeel
- Sharpless, Norman E.
- Wong, Kwok-Kin
- ORCID
- Ji, Hongbin
- Ramsey, Matthew R.
- Hayes, D. Neil
- Wu, Michael C.
- Shimamura, Takeshi
- Perera, Samanthi A.
- Liang, Mei-Chih
- Bao, Lei
- Chen, Liang
- Koivunen, Jussi
- Chirieac, Lucian R.
- Padera, Robert F.
- Bronson, Roderick T.
- Lindeman, Neal I.
- Christiani, David C.
- Lin, Xihong
- Shapiro, Geoffrey I.
- Johnson, Bruce E.
- Meyerson, Matthew
- Kwiatkowski, David J.
- Bardeesy, Nabeel
- Sharpless, Norman E.
- Wong, Kwok-Kin
- Venue
- Nature
- Published
- 2007-08-05
- Volume
- 448
- Issue
- 7155
- Pages
- 807-810
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2134964552
- Cited by
- 1,064
- References
- 36
- Citations by year
- 2026: 30 · 2025: 43 · 2024: 44 · 2023: 66 · 2022: 50 · 2021: 71 · 2020: 51 · 2019: 66 · 2018: 61 · 2017: 56 · 2016: 54 · 2015: 72 · 2014: 83 · 2013: 65 · 2012: 52
- FWCI
- 24.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- LKB1, STK11, lung cancer, tumour suppressor, metastasis, squamous cell carcinoma, non-small cell lung cancer, KRAS, p53, Ink4a/Arf, CDKN2A, tumor differentiation, Peutz-Jeghers syndrome, metastasis-promoting genes
- MeSH terms
- AMP-Activated Protein Kinase Kinases, Animals, Carcinoma, Non-Small-Cell Lung, Cell Differentiation, Disease Models, Animal, Humans, Lung Neoplasms, Neoplasm Metastasis, Genes, ras, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Genes, p53, Protein Serine-Threonine Kinases, Genes, p16, Gene Expression Profiling, Cell Line, Tumor, Mice, Genes, Neoplasm, AMP-Activated Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.